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Abstract:
78-year-old female with past medical history of acromegaly
status post pituitary adenoma status post resection presents to
the emergency department with abdominal pain. ED workup was
not significant for any acute intra-abdominal abnormalities;
however, incidental finding of hyperkalemia was pertinent to the
visit. Patient was treated in the ED for her condition but her
potassium levels remained elevated despite repeated saline
infusions. Patient was ultimately admitted to the hospital where
it was discovered that she had recently been switched from
octreotide injections to an oral somatostatin analogue Mycapssa.
We believe that this patient’s hyperkalemia was caused by
octreotide-induced insulin suppression and resultant impaired
cellular potassium uptake. Although octreotide has a wide
variety of medical applications it can/should be used with
caution as complications arising from elevated potassium can be
potentially dangerous.

Conclusion:

Case Presentation:
Patient is a 78 year old with past medical history of pituitary
adenoma, ovarian cancer, partial bowel resection secondary to
diverticulitis with colostomy placement, mixed hyperlipidemia,
stage 3 chronic kidney disease, and acromegaly, who presented
to the Emergency Department at Jefferson Stratford for the
evaluation of left lower quadrant pain. Patient states that her
condition began approximately 1.5 weeks prior. Patient reports
inciting event (lifting heavy cat litter); however, she denies any
frank/overt trauma. Patient described her pain as “pulling”,
constant, progressive, 7/10 at time of ED evaluation and nonradiating. Patient endorsed that pain was exacerbated by
standing and/or walking. Patient stated that pain was alleviated
by warm compresses. Patient endorsed persistent diarrhea but
denied any other associated symptoms. ED workup at that time
was negative for any acute intra abdominal abnormalities;
however, BMP was significant for the incidental finding of
hyperkalemia. EKG showed no significant changes. Patient was
subsequently treated with multiple boluses of IV saline in the ED
but her potassium remained elevated at 6.1. Upon further
questioning, it was discovered that the patient had been recently
switched 10 days prior from regularly scheduled injections of
octreotide to an oral somatostatin analogue called Mycapssa by
her endocrinologist. According to the patient, she had been on
octreotide for treatment of refractory acromegaly status post
pituitary resection. The patient was ultimately admitted to the
hospital for cardiac monitoring and treated with insulin/dextrose
and calcium gluconate for her elevated potassium. In addition,
the patient’s octreotide was withheld due to concern that this
medication could be directly contributing to her condition.
Endocrinology was consulted on the case and after establishing
that her IGF-1 levels were normal, it was deemed appropriate for
the patient to remain off of this medication until she could follow
up with her own endocrine specialist after discharge home.

Octreotide molecule (bing.com)

The mechanism by which octreotide analogues precipitate elevated
potassium levels is via the suppression of endogenous pancreatic
insulin secretion and resultant impaired cellular potassium uptake. It
is for this very trait that octreotide is often utilized for the treatment
of sulfonylurea toxicity, a medication which conversely induces
endogenous insulin secretion in diabetic patients. Other causes of
hyperkalemia were also considered in this patient, including factors
that pertain to decreased potassium excretion (renal failure,
potassium sparing diuretics, ace inhibitors, aldosterone deficiency),
increased potassium load (tumor lysis, rhabdomyolysis, potassium
supplementation), cellular potassium shifts (acidosis, beta blockade,
digitalis toxicity); however, no other sources for the patient’s
elevated potassium levels could be identified. There is limited data
regarding the safety of octreotide regarding hyperkalemia, especially
in those patients who are already predisposed to having elevated
levels of potassium (dialysis patients) and those using certain
medications (beta blockers, ace inhibitors, digoxin, spironolactone).
It should therefore be utilized with caution and potassium levels
closely monitored under such circumstances.
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Discussion:
Octreotide (Sandostatin, Mycapssa) is a synthetic somatostatin analog that is
a potent inhibitor of growth hormone, glucagon and insulin via competitive
agonism of somatostatin receptors SSTR2 and SSTR5. It was first synthesized
in 1979 by chemist Wilfried Bauer and was approved for use in the United
States in 1988. As it resembles somatostatin it can precipitate many of the
same physiologic reactions as its hormonal counterpart, such as inhibition of
gastrin, cholecystokinin, glucagon, growth hormone, insulin, secretin,
pancreatic polypeptide, TSH, and vasoactive intestinal peptide. In addition,
octreotide can also reduce gastrointestinal motility, inhibit contraction of the
gallbladder, cause vasoconstriction, decrease pancreatic/intestinal fluid
secretion and alleviate portal vein pressure. Consequently, this medication
has longstanding and valued application among diagnosis and treatment of a
wide variety of diseases, including (but not limited to): endocrine disorders
(acromegaly, gigantism, congenital hyperinsulinism, Grave’s disease, diabetic
retinopathy, and sulfonylurea-induced hypoglycemia), pituitary adenomas
(somatotropinoma, thyrotropinoma), non-endocrine malignancy (breast,
colon, prostate, lung, hepatocellular, tumors), digestive diseases (refractory
diarrhea, gastrointestinal hemorrhage, carcinoid syndrome, intestinal fistula)
and even foreign body ingestion. Similarly, there are many well-known/wellstudied adverse effects of octreotide when used in the treatment of the
aforementioned disorders. The most common side effects documented
include (but are not limited to) headache, hypothyroidism, arrhythmia,
gastrointestinal reactions (cramps, nausea, vomiting, diarrhea, constipation),
gallstones, and, most relevant to our case study, hyperkalemia.
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